4basebio

88Q.DE

Biotechnology · Healthcare

Price

€5.25

+0.15 (+2.94%)

Market Cap

€81.3M

Exchange

Frankfurt Stock Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Weak

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+25.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 12.3M (2021) → 15.5M (2025)

Winston Score History

The full picture

4basebio is a small British biotechnology company that makes synthetic DNA for use in gene therapies and vaccines. Its main product is a type of engineered DNA called synthetic linear covalently closed (sLCC) DNA, which drug developers use as a building block when creating treatments for genetic diseases and cancer. The company sells primarily to pharmaceutical and biotech research organizations that are developing next-generation medicines.

4basebio earns revenue by selling its DNA materials and providing related services to research and development customers, though it is still in an early commercial stage and currently spends far more than it earns. It operates mainly in Europe, with a research and manufacturing base in the UK and Germany, and its market cap sits around $100 million. The key growth driver is rising demand for non-viral DNA delivery in gene therapy, but the main risk is that the company is burning cash heavily, which means it may need to raise more money to survive long enough to reach profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-14.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-18.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

£5M/ year

↑ Rising (+9% vs prior year)

302.4% of revenue

16.8x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

62.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~7 months

£18M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

4basebio is putting 302% of revenue into R&D and that number is rising. That's 16.8x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-57.2%

Thin — -57.2% gross margin

Profit after running costs

Operating Margin

-1637.0%

Losing money on operations — -1637.0%

Return on the money invested

ROCE

-64.4%

Weak — -64.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+81.0%

Fast-growing sales (+81.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-899.0%

Burning cash (-899.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.56

Elevated debt (1.56)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial